Printer Friendly

INTERPHARM LABORATORIES LTD. REPORTS THIRD QUARTER AND NINE MONTHS EARNINGS AND INCOME

 INTERPHARM LABORATORIES LTD. REPORTS THIRD QUARTER
 AND NINE MONTHS EARNINGS AND INCOME
 NESS-ZIONA, ISRAEL, Nov. 13 /PRNewswire/ -- InterPharm Laboratories Limited (NASDAQ: IPLLF) today reported revenues of U.S. $12.9 million for the third quarter ending Sept. 30, 1992, compared with $9.1 million for the same period last year, an increase of 41 percent.
 Revenues for the nine months ending Sept. 30, 1992 rose 44 percent to $36.3 million, compared with $25.2 million during the same period in 1991. Net income rose 39 percent to $4.7 million or 75 cents per share. This compares with $3.4 million or 54 cents per share for the first nine months of 1991.
 Commenting on these results, Dr. Yoram Karmon, chairman and chief executive officer of the company, remarked: "This performance was achieved primarily as a result of increased sales of Frone(R), our human fibroblast beta interferon. We continue to expand our production facilities in order to meet the growing demand for Frone."
 InterPharm Laboratories Ltd. is a member of The Ares-Serono Group, a worldwide developer and marketer of pharmaceutical and diagnostic products, with executive headquarters in Geneva (Switzerland) and operational headquarters in Boston (U.S.A.). The Group operates subsidiaries and manufacturing facilities in more than 20 countries. InterPharm's shares are traded over-the-counter in the U.S.
 INTERPHARM LABORATORIES
 Summary of Unaudited Results
 Three Months Ended Nine Months Ended
 Sept. 30 Sept. 30
 1992 1991 1992 1991
 Revenues $12,906,854 $9,145,962 $36,324,683 $25,164,739
 Operating
 profit 1,812,294 1,685,054 4,505,958 3,478,872
 Financial expense
 net 54,043 125,766 136,353 106,230
 Net income after
 tax 1,766,220 1,559,288 4,701,370 3,372,642
 Earnings per
 ordinary share 28 cents 25 cents 75 cents 54 cents
 Weighted average
 number of
 ordinary shares
 outstanding 6,242,385 6,242,385 6,242,385 6,240,022
 -0- 11/13/92
 /CONTACT: Gina Cella, 617-982-9000, for Interpharm Laboratories/
 (IPLLF) CO: Interpharm Laboratories ST: Massachusetts IN: MTC SU: ERN


CH -- NE002 -- 0595 11/13/92 10:13 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 13, 1992
Words:355
Previous Article:CONSUMER PRICE INDEX FOR THE WEST -- OCTOBER 1992
Next Article:RAMTRON HOLDINGS GROUP CONSOLIDATES IN THE U.S.
Topics:


Related Articles
INTERPHARM LABORATORIES REPORTS 1991 THIRD QUARTER AND NINE MONTHS SALES AND EARNINGS
INTERPHARM LABORATORIES REPORTS AN INCREASE IN SALES AND NET INCOME IN 1991
INTERPHARM LABORATORIES LTD. REPORTS EARNINGS AND INCOME FOR THE SECOND QUARTER OF 1992
INTERPHARM LABORATORIES LTD. REPORTS 1993 FIRST QUARTER RESULTS
INTERPHARM LABORATORIES LTD. REPORTS REVENUES AND NET INCOME FOR THE SECOND QUARTER OF 1993
INTERPHARM LABORATORIES LTD. REPORTS REVENUES AND INCOME FOR THE THIRD QUARTER OF 1993
INTERPHARM LABORATORIES LTD. REPORTS 1993 RESULTS OF OPERATIONS
INTERPHARM LABORATORIES LIMITED REPORTS 1994 FIRST QUARTER RESULTS
INTERPHARM LABORATORIES LIMITED REPORTS A NEGATIVE IMPACT ON SALES OF FRONE IN ITALY
INTERPHARM LABORATORIES LTD. REPORTS 1994 THIRD QUARTER RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters